Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme
Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose oxidase (MtbDprE1) acts in concert with decaprenylphosphoryl-β-d-ribose 2-epimerase (MtbDprE2) and catalyzes the epimerization of DPR into DPA. DPA is the sole precursor for synthesis of arabinogalactan and lipoarabinomannan in the mycobacterial cell wall. MtbDprE1 is a unique antimalarial drug target and many covalent and non-covalent inhibitors against MtbDprE1 have been studied for their antituberculosis activities. In the current study, we have purified MtbDprE1 enzyme and synthesized six sulfur-rich 2-mercaptobenzothiazole and 1, 2, 3-triazole conjugated ligands and performed binding analysis with MtbDprE1. All ligands have shown competitive binding, as observed for other covalently and noncovalently bound MtbDprE1 inhibitors. Molecular docking analysis of six ligands with MtbDprE1 shows that they occupy the substrate binding pocket of MtbDprE1 and are stabilized by hydrogen bonds and van der Waals interactions. Our study shows that sulfur-rich 2-mercaptobenzothiazole ligands act as specific inhibitors against MtbDprE1 and could be used as antituberculosis agents.
KeywordsMycobacterial cell wall synthesis enzyme In vitro MtbDprE1-FAD ~ ligand binding In silico MtbDprE1-FAD-ligand structure
Funding for the current work was supported by a grant from the Department of Biotechnology (No. PAC-SLS-AKS-DBT-01131216-737) to Ajay K Saxena. Partial funding from UGC resource networking, DST–PURSE, and UPE-II grants from Jawaharlal Nehru University are gratefully acknowledged. Sumita Karan and Vipin K. Kashyap were supported by UGC-NET research fellowship. The authors thank Amarjeet Kumar, Prof. N. SubbaRao’s student, who helped tremendously in docking analysis of these compounds. The authors thank AIRF facility of JNU for conducting the surface plasmon resonance experiment.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 1.World Health Organization (2015) Global Tuberculosis ReportGoogle Scholar
- 4.Mikusova K, Huang HR, Yagi T, Holsters M, Vereecke D, D’Haeze W, Scherman MS, Brennan PJ, McNeil MR, Crick DC (2005) Decaprenylphosphoryl arabinofuranose, the donor of the d-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J. Bacteriol. 187(23):8020–8025CrossRefGoogle Scholar
- 15.Tiwari R, Miller PA, Chiarelli LR, Mori G, Šarkan M, Centárová I, Cho S, Mikušová K, Franzblau SG, Oliver AG, Miller MJ (2016) Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired by BTZ043. ACS Med. Chem. Lett. 7(3):266–270CrossRefGoogle Scholar
- 19.Bessonov K, Vassall KA, Harauz G (2017) Docking and molecular dynamics simulations of the Fyn-SH3 domain with free and phospholipid bilayer-associated 18.5-kDa myelin basic protein (MBP) - Insights into a non-canonical and fuzzy interaction. Proteins prot.25295Google Scholar
- 23.Al-Khayyat MZ, Al-Dabbagh AG (2016) In silico prediction and docking of tertiary structure of LuxI, an inducer synthase of Vibrio fischeri. Rep Biochem Mol Biol 4(2):66–75Google Scholar
- 25.Matossian M, Vangelderen C, Papagerakis P, Zheng L, Wolf GT, Papagerakis S (2014) In silico modeling of the molecular interactions of antacid medication with the endothelium: novel therapeutic implications in head and neck carcinomas. Int. J. Immunopathol. Pharmacol. 27(4):573–583CrossRefGoogle Scholar